Analysis of Mortality Data From Cancer Screening Studies: Looking in the Right Window

Background: Appropriate statistical analysis is required to measure the impact of early detection and treatment of cancer. The current practice of using cumulative mortality ignores both (1) the delay between early treatment and the time that any averted deaths would have otherwise occurred, and (2) cessation of these delayed benefits some time after screening is discontinued. Methods: We use time-specific mortality density ratios to estimate the mortality ratio in the “window of influence.” We then use time-specific incidence density ratios to assess the extent to which the removal of polyps and other possibly precancerous lesions detected by fecal occult blood screening reduces the incidence of colorectal cancer. Results: Applied to a theoretical example, the current practice of using cumulative mortality substantially underestimates the reduction in mortality achievable by early treatment. If there is sufficient time for the full impact to emerge, time-specific mortality patterns provide a more accurate measure. In a previous analysis of the screening study, the reduction in cumulative incidence in the screened groups was just under 20%. In our reanalysis, yearly incidence density ratios indicate that had screening not been interrupted, there might have been a 40% reduction in incidence. Conclusions: Time-specific mortality ratios provide a more sensitive measure of the effects of early detection and treatment. Measures based on cumulative mortality are diluted by inclusion of deaths that occur soon after the initiation of screening as well as deaths that occur too long after the cessation of screening.

[1]  J. Cuzick,et al.  A case–control study to estimate the impact on breast cancer death of the breast screening programme in Wales , 2004, Breast Cancer Research.

[2]  G. Friedman,et al.  Screening in chronic disease , 2004, Cancer Causes & Control.

[3]  S. Walter Mammographic screening: case-control studies. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  W. Atkin,et al.  Options for Screening for Colorectal Cancer , 2003, Scandinavian journal of gastroenterology. Supplement.

[5]  Michael J Barry,et al.  Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut , 2002, BMJ : British Medical Journal.

[6]  John Werth,et al.  Mammographic screening: no reliable supporting evidence? , 2002, The Lancet.

[7]  P. Albertsen Needs assessment of women with urinary incontinence in a district health authority. , 2002, The Journal of urology.

[8]  P. Albertsen Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2002, The Journal of urology.

[9]  I. Bairati,et al.  PSA screening and prostate cancer mortality. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  P. Gøtzsche,et al.  Mammographic screening: no reliable supporting evidence? , 2002, The Lancet.

[11]  D. Gunnell,et al.  International trends in prostate‐cancer mortality in the “PSA era” , 2001, International journal of cancer.

[12]  L M Schuman,et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.

[13]  P C Prorok,et al.  Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. , 2000, Journal of the National Cancer Institute.

[14]  D. Gunnell,et al.  Comparison of trends in prostate-cancer mortality in England and Wales and the USA , 2000, The Lancet.

[15]  Peter C Gøtzsche,et al.  Is screening for breast cancer with mammography justifiable? , 2000, The Lancet.

[16]  T. Church,et al.  Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. , 1999, Journal of the National Cancer Institute.

[17]  A S Whittemore,et al.  Prostate cancer incidence and mortality in the United States and the United Kingdom. , 1998, Journal of the National Cancer Institute.

[18]  SCREENING FOR BREAST CANCER IN WOMEN AGED 40-49 YEARS , 2022 .